Novo Nordisk has entered a multi-year research collaboration with Replicate Biosciences, valued at up to $550 million, to develop new therapies for obesity, type 2 diabetes, and related cardiometabolic diseases using self-replicating RNA (srRNA) technology. The partnership grants Novo Nordisk worldwide licensing rights to Replicate’s srRNA platform, aiming to leverage enhanced protein expression durability and tunability. This initiative aligns with Novo Nordisk’s strategy to broaden its cardiometabolic pipeline by integrating novel RNA modalities, complementing prior investments and collaborations within RNA therapeutic spaces.